Thank you for taking our quiz! How did you do? 1) According to an AAO IRIS® Registry Analysis, the overall prevalence of dry eye disease (DED) was about 30% in patients 3 months prior cataract surgery, but only what percent of...
It’s no question that advancements in the treatment of dry eye were impressive at AAO 2020....
AAO 2020 eBook – Dry Eye Featuring Impact of Dry Eye Signs & Symptoms on Work Productivity Severe DED in Chronic GVHD: Assessing the Role of Serum Vitamin A Examining the Role of Microneuromas Markers in Neuropathic...
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Dry eye disease (DED) is a highly prevalent syndrome that manifests with symptoms that include constant irritation, burning or stinging sensations, and feelings of grittiness in the eyes. “DED is a chronic pain syndrome often...
Previous research has shown that patients undergoing hematopoietic stem cell transplantation (HSCT) for hematologic malignancies, such as leukemia and lymphoma, are at a high risk of developing graft-versus-host disease (GVHD)....
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability. The disease can significantly decrease quality of life as it impacts an...
According to published research, as many as 77% of patients with cataracts present with common signs of dry eye disease (DED) prior to surgery. These signs include corneal staining, short tear breakup time, and hyperosmolarity,...
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
New data from the phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults were presented at the AAO 2020 Virtual Annual Meeting. A single...
Contributing to this article, Shahzad I. Mian, MD, Professor, Ophthalmology and Visual Sciences, Vice Chair, Clinical Sciences and Learning, Kellogg Eye Center, Michigan Medicine Previous research has shown that patients...
In order assess the time to corneal epithelization with photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL) as a first-line treatment for early infectious corneal ulcers and to compare PACK-CXL...
